DBH Student Work Spotlight: Turmeric’s Potential to Treat Post-traumatic Stress Disorder

The literature generally acknowledges an inflammation and post-traumatic stress disorder interconnection. However, the precise etiology of post-traumatic stress disorder-induced inflammation is unknown and appears complex (Hori & Kim, 2019; Quinones et al., 2020). At a basic level, inflammation is observed in many human diseases and is often defined by the body’s immune response to infection or injury, including those impairing autonomic nervous system functioning (Chen et al., 2018; Medzhitov, 2021; Quinones et al., 2020). Two psychotropic medications are evidenced in treating post-traumatic stress disorder, both of which are selective serotonin reuptake inhibitors that produce anti-inflammatory reactions (Hori & Kim, 2019).

This literature review examines the post-traumatic stress disorder inflammatory response and interventions capable of disrupting the underlying mechanism that leads to chronic inflammation in patients experiencing post-traumatic stress disorder. Specifically, this literature first seeks to understand the underlying inflammation response induced by post-traumatic stress disorder. Then it reviews the use of turmeric (curcumin) to mitigate inflammation as an alternative to prescription drugs and a complementary intervention to psychotherapy.

EBSCO, Google Scholar, and PubMedCentral were used to identify data. Keywords included post-traumatic stress disorder, PTSD, inflammation, treatment, curcumin, turmeric, biomarkers, and comorbid.

Literature Review

As detailed in the Diagnostic and Statistical Manual of Mental Disorders, post-traumatic stress disorder results from traumatic experiences (American Psychiatric Association, 2022). Specifically, the American Psychiatric Association (2022) defines post-traumatic stress disorder as exposure to death, injury, or sexual violence; intrusive, trauma-related symptoms following exposure; trauma-related avoidance behaviors; trauma-induced changes in cognition, mood, arousal, and reactivity. These symptoms impair functioning and may occur with dissociative symptoms, such as depersonalization and derealization. Inherent in the experience of many diagnosed with post-traumatic stress disorder are impairments to fear extermination, hyperarousal, executive functioning, verbal and working memory, learning difficulties, anxiety, and depression (Hori & Kim, 2019; Lee & Lee, 2018; Quinones et al., 2020).

Genetics, gender, and societal issues–like racism, sexism, homophobia, and transphobia– may play an essential role in post-traumatic stress disorder onset. Sun et al. (2020) noted that the inheritance rate of post-traumatic stress disorder ranges between 24% and 72% in twin studies. Those assigned males at birth are at lower risk than those assigned female at birth for developing post-traumatic stress disorder (Sun et al., 2020). Those identifying as Hispanic, African American or Black, and Native American Indians experience a higher prevalence of post-traumatic stress disorder (American Psychiatric Association, 2022). Additionally, the United States Department of Veteran Affairs (n.d.) identifies post-traumatic stress disorder risk among the LGBT community.

Individuals experiencing post-traumatic stress disorder are considered at high risk for mortality and comorbidities, such as Alzheimer’s disease, autoimmune disease, traumatic brain injury, cardiovascular disease, type 2 diabetes, irritable bowel syndrome, metabolic syndrome, and obesity (Cooper et al., 2023; Hori & Kim, 2019; Kim et al., 2020; Quinones et al., 2020; Sun et al., 2020). Inflammation is observed in these diseases (Cooper et al., 2023; Furman et al., 2019; Hori & Kim, 2019), which suggests that post-traumatic stress disorder enables a dysregulated immune system inflammation response (Hori & Kim, 2019; Quinones et al., 2020). The immune system’s inflammation response to harmful stimuli may partly explain this dysregulation (Chen et al., 2018; Kim et al., 2020). Furthermore, this dysregulated inflammatory response impairs fear extinction in those diagnosed with post-traumatic stress disorder (Quinones et al., 2020).

Neuroscience-Informed Considerations

Individuals experiencing post-traumatic stress disorder can misinterpret tolerable situations as threatening when faced with trauma-related stimuli, which may suggest fear network dysfunction (Quinones et al., 2020). Quinones et al. (2020) identify the medial prefrontal cortex, amygdala, and hippocampus as playing fear network roles. In animal studies, the amygdala plays a central role in fear learning, memory-based expression, and fear extinction. Kim et al. (2020) concur with Quinones that post-traumatic stress disorder’s prefrontal cortex, hippocampus, and amygdala dysregulation are associated with inflammatory response, as seen via neuroimaging.

Recognition and early treatment of adverse childhood experiences may be crucial to regulating trauma-related inflammation. Those exposed to trauma in early life may experience lasting changes to the genes regulating inflammation (Sun et al., 2020). As a result of this early life stress-inducing inflammation, cognitive, neural, and immune systems may be adversely affected (Quinones et al., 2020). It is conceivable that childhood adversities produce chronic inflammation resulting in health concerns throughout life (Hori & Kim, 2019).

Inflammation resulting from post-traumatic stress disorder remains under investigation. Quinones et al. (2020) identify the hippocampus’ role in environmental threat assessment during fear acquisition and extinction learning. These authors also point to increased amygdala activity in individuals experiencing post-traumatic stress disorder, thus likely enhancing fear recall. Quinones et al. (2020) suggest that increased medial prefrontal cortex activity during fear conditioning and decreased activity during fear extinction learning may enable post-traumatic stress disorder symptom continuation. Additionally, these authors noted the anterior cingulate cortex’s important role in emotion appraisal and regulation, and threat bias attention, which activates the sympathetic division of the autonomic nervous system (Quinones et al., 2020).

Quinones et al. (2020) and Hori and Kim (2019) align post-traumatic stress disorder-related inflammation with a heightened stress response, which they connect to changes in the hypothalamic-pituitary-adrenal (HPA) axis and autonomic nervous system. The HPA axis is crucial to homeostatic maintenance (Hori & Kim, 2019). A hypoactive HPA axis combined with a hyperactive sympathetic nervous system is evident in individuals experiencing post-traumatic stress disorder (Hori & Kim, 2019). This helps to explain the HPA axis dysregulation linked to inflammation across numerous post-traumatic stress disorder studies (Quinones et al., 2020). Additionally, inflammation suppresses homeostatic controls, which can result in dysregulation of the inflammatory response (Medzhitov, 2021).

Quinones et al. (2020) acknowledge limited evidence identifying the precise mental mechanisms inducing inflammation in post-traumatic stress disorder-diagnosed individuals. However, a growing body of research is investigating the multiple and complex ways post-traumatic stress disorder induces an inflammatory response. Research identifies a potential bidirectional model capable of maintaining post-traumatic stress disorder (Quinones et al., 2020). Evidence points to the detrimental effect of inflammation on cognition, which may contribute to post-traumatic stress disorder symptomatology. However, the research indicates chronic stress causes inflammation (Hori & Kim, 2019; Quinones et al., 2020).

Bidirectional Treatment Opportunity

Today, the primary post-traumatic stress disorder treatment is trauma counseling as soon as possible following exposure. However, individuals experiencing post-traumatic stress disorder are less likely to seek treatment (Kim et al., 2020; Quinones et al., 2020). Nevertheless, the evidence linking post-traumatic stress disorder to inflammation is significant.

Elevated interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a) serum levels are evident in those experiencing post-traumatic stress disorder. Elevated C-reactive protein, created by the liver, is also evident. When elevated, these biomarkers indicate inflammation (Ahmad et al., 2019; Hori & Kim, 2019; Kim et al., 2020; Quinones et al., 2020). IL-6 and TNF-a are pro-inflammatory cytokines (Sun et al., 2020) that are observed to cross the blood-brain barrier and may be implicated in inflammation-causing cognitive impairment (Hori & Kim, 2019; Kim et al., 2020). As such, C-reactive protein and cytokines like IL-6 and TNF-a may create an environment capable of sustaining post-traumatic stress disorder symptoms, thus giving way to pharmacological treatment in addition to or in place of trauma counseling for those resistant to psychotherapy (Quinones et al., 2020).

According to Hori and Kim (2019) and confirmed by the American Psychological Association (n.d.), the US Food and Drug Administration approved two selective serotonin reuptake inhibitors, sertraline (Zoloft) and paroxetine (Paxil), to treat post-traumatic stress disorder. Sun et al. (2020) suggest that selective serotonin reuptake inhibitors used following traumatic experiences can reduce long-term harm to health impairment associated with inflammation related to post-traumatic stress disorder.

The United States Department of Veteran Affairs (n.d.) and the American Psychological Association (n.d.) identify selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors as promising psychotropic medications to treat post-traumatic stress disorder. These medications decrease neuroinflammation by reducing cytokines or regulating complex inflammatory pathways and, as such, demonstrate anti-inflammatory properties (Dionisie et al., 2021; Hori & Kim, 2019).

Additional drugs are being studied. Hori and Kim (2019) identified non-steroidal anti-inflammatory drugs, glucocorticoids, angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers, and cannabis are being examined. Since pro-inflammatory cytokines are evidenced in individuals experiencing post-traumatic stress disorder (Kim et al., 2020), anti-inflammatory medications may prove helpful. Consistent among the studied drugs is their anti-inflammatory effect (Barnes, 1998; Hori & Kim, 2019; Huang et al., 2021; Kopustinskiene et al., 2022; Nguyen & Brewster, 2023; Quinones et al., 2020).

Turmeric for Post-Traumatic Stress Disorder Treatment

Psychopharmacological research regarding treating post-traumatic stress disorder-induced inflammation is limited (Hori & Kim, 2019; Quinones et al., 2020). Turmeric, however, is widely accepted for its anti-inflammatory effect (Memarzia et al., 2021) and may prove effective in treating post-traumatic stress disorder-induced inflammation due to the root’s anti-inflammatory effect on pro-inflammatory cytokines (Quinones et al., 2020). However, additional research is needed to fully understand the use of turmeric to treat post-traumatic stress disorder-induced inflammation. Herein, turmeric’s anti-inflammatory properties are examined as an alternative treatment to selective serotonin reuptake inhibitors and other prescribed off-label use medications with anti-inflammatory effects.

Turmeric is a member of the Zingiberaceae family (Memarzia et al., 2021). Historically used as a medicinal herb to treat numerous diseases in Chinese, Indian, Islamic traditional, and Ayurvedic medicines, turmeric is grown in tropical and subtropical regions and made from the plant’s rhizome (Akaberi et al., 2021; Memarzia et al., 2021; Singeltary, 2020; Yadav et al., 2015). Generally, the plant grows well in sand or clay, produces yellowish flowers, and reaches a height of three to five feet (Ahmad et al., 2019). As turmeric is available over the counter and without prescription, it is not a scheduled drug and is considered a safe dietary supplement (Smith et al., 2023).

Turmeric Pharmacodynamics

According to Lee and Lee (2018), Zhou et al. (2022), and Smith et al. (2023), the turmeric mechanism of action in post-traumatic stress disorder requires additional study. To that end, several studies sought to identify the mechanism of action. Memarzia et al. (2021) identified turmeric’s anti-inflammatory properties, including decreased histamine-induced inflammation, increased cortisol production, and improved blood circulation, contributing to inflammation reduction. Smith et al. (2023) propose cytokine signaling inhibition as the mechanism of action, supported in early research according to Yadav et al. (2015).

As mentioned, two primary pro-inflammatory cytokines and one protein are biomarkers consistently identified in individuals experiencing post-traumatic stress disorder. These biomarkers include C-reactive protein, TNF-a and IL-6. Turmeric reduces levels of these inflammatory biomarkers (Ahmad et al., 2019; Yadav et al., 2015; Zhou et al., 2022), identifying turmeric as a likely effective treatment for post-traumatic stress disorder.

Turmeric is well-positioned for post-traumatic stress disorder study in human trials, although most testing of turmeric on post-traumatic stress disorder is done on rats and mice. Turmeric testing on rats showed a reduction of anxiety and freeze-related fear behaviors by reversing serotonin dysfunction (Lee & Lee, 2018). Monsey et al. (2015) added that a diet rich in turmeric promoted the disruption of fear memories in rates. Other rat studies provided evidence of reduced serotonin in the hippocampus and amygdala and demonstrated the resolution of post-traumatic stress (Lee & Lee, 2018; Nakahara, 2021). Furthermore, Lopresti (2022) observed turmeric’s efficacy in depression improvement in mice, resulting from the supplement’s serotonin stimulation effect. Aubry et al. (2019) observed turmeric’s helpfulness in improving resilience in mice. Although further studies are needed, turmeric has the potential to positively influence the brain regions of humans experiencing post-traumatic stress disorder.

Across the literature, no single effective dose was identified, and turmeric is generally considered safe, although a maximum safe dose requires identification (Smith et al., 2019). Ahmad et al.(2019) reported no genotoxicity. However, Smith et al. (2023) disagreed. They noted possible genetic risk factors associated with turmeric use by Caucasians, females assigned at birth, and those experiencing human leukocyte antigen (HLA) type b. Singletary (2020) generally recommends dose and use caution resulting from a need for additional clinical information regarding dose safety and drug interactions. As mentioned, those assigned female at birth are at a higher risk for post-traumatic stress disorder. As such, using turmeric to treat post-traumatic stress disorder may further benefit those assigned female at birth.

Turmeric Pharmacokinetics

Across the literature, turmeric demonstrates poor oral absorption due to low water solubility. Singletary (2020) identified “poor water solubility, low intestinal absorption, and rapid metabolic degradation” as turmeric absorption inhibitors. To enhance turmeric absorption, turmeric is often encapsulated with piperine (black pepper), ginger, or oil (Dei Cas & Ghidoni, 2019; Memarzia et al., 2021; Singletary, 2020; Smith et al., 2023; Zhou et al., 2022). However, Ahmad et al. (2019) noted increased absorption of turmeric when administered intravenously.

Once orally administered, turmeric first enters the stomach and remains stable due to its ability to withstand acidic conditions. From the stomach, turmeric enters the gastrointestinal tract, where it remains for approximately 30 minutes with low absorption. Then, it moves to the liver for metabolization before entering the intestinal lumen for excretion via the colon (Dei Cas & Ghidoni, 2019; Memarzia et al., 2021).

Turmeric Pharmacology

The main component of turmeric is curcumin. The primary bioactive ingredients include diarylheptanoids (curcuminoids), bisdemethoxycurcumin, demethoxycurcumin, and diferuloylmethane. Still, more bioactive plant components are evident (Lee & Lee, 2018; Memarzia et al., 2021; Singletary, 2020). The primary component, curcumin, known chemically as 1,7-bis(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione (Ahmad et al., 2019; Memarzia et al., 2021; Peng et al., 2021), is evidenced in producing neuroprotective, anti-inflammatory, and immunomodulatory effects (Ahmad et al., 2019; Akaberi et al., 2021; Lee & Lee, 2018; Memarzia et al., 2021; Zhou et al., 2022). These anti-inflammatory effects inform the potential for using turmeric to treat post-traumatic stress disorder-related inflammation (Mavaddatiyan et al., 2022).

Turmeric Pharmacotherapeutics

Across the history of therapeutic use, Tumeric has demonstrated effectiveness in the treatment of heart disease, arthritis, cancer, gastrointestinal disorder, liver dysfunction, urinary tract infections, allergies, metabolic syndrome, diabetes, pain, wound healing, inflammation, and immune dysregulation disorders (Ahmad et al., 2019; Dehzad et al., 2023; Dei Cas & Ghidoni, 2019; Memarzia et al., 2021; Singletary, 2020; Yadav et al., 2015; Zhou et al., 2022). Additionally, turmeric effectively treats neurological and psychiatric disorders like Parkinson’s disease, Alzheimer’s disease, mood disorders, and memory disorders, neuroinflammation (Ahmad et al., 2019; Akaberi et al., 2021; Lee & Lee, 2018; Nakahara, 2021). As many of these illnesses demonstrate inflammation, turmeric will likely produce anti-inflammatory effects in those experiencing post-traumatic stress disorder.

Turmeric Toxicology

Generally, the United States Food and Drug Administration considers turmeric safe (Memarzia et al., 2021; “Turmeric,” 2022). Potential side effects include itching, rash, tongue redness, headache, tachycardia, flatulence, diarrhea, nausea, yellow stool, abdominal pain, and constipation (Ahmad et al., 2019; Memarzia et al., 2021; “Turmeric,” 2022). Smith et al. (2023) observed liver injury in a single case which resolved with discontinuation. Although considered safe during pregnancy (Ahmad et al., 2019), assessment of use requires close attention and is not suggested for use during breastfeeding since curcumin restricts milk production (“Turmeric,” 2022). Ahmad et al. (2019) also noted the potential for turmeric to alter other medications an individual uses. As such, clinical pharmacist consultation is recommended.

Conclusion

Turmeric brings to bear a body of historical use regarding the efficacy of its primary component, curcumin, to relieve symptoms associated with many diseases. Although clinical trials provide an opportunity for the specific identification of the practical and safe dose in humans, animal models provide a pathway to understanding turmeric’s effect on the neurological systems implicated in post-traumatic stress disorder. Considering the impact of turmeric on several post-traumatic stress disorder risk populations and comorbidities, its fast-acting impact compared to selective serotonin reuptake inhibitors, and its general availability in the market, turmeric may serve as the preferred complementary intervention to psychotherapy since it demonstrates the least harmful side effects for the majority of patients. However, further research is required to precisely understand the effect of turmeric on genetics, the fear network, the hypothalamic-pituitary-adrenal (HPA) axis, and the autonomic nervous system, in addition to the biomarkers implicated in post-traumatic stress disorder.

References

Ahmad, R. S., Hussain, M. B., Sultan, M. T., Arshad, M. S., Waheed, M., Shariati, M. A., Plygun, S., & Hashempur, M. H. (2019). Biochemistry, safety, pharmacological activities, and clinical applications of turmeric: A mechanistic review. Evidence-based Complementary and Alternative Medicine. https://doi.org/10.1155/2020/7656919

Akaberi, M., Sahebkar, A., & Emami, S. A. (2021). Turmeric and curcumin: From traditional to modern medicine. Advances in Experimental Medicine and Biology, 1291, 15–39. https://doi.org/10.1007/978-3-030-56153-6_2

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787

American Psychological Association (n.d.). Medications for PTSD. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder. Retrieved on April 24, 2023, from https://www.apa.org/ptsd-guideline/treatments/medications

Aubry, A. V., Khandaker, H., Ravenelle, R., Grunfeld, I. S., Bonnefil, V., Chan, K. L., Cathomas, F., Liu, J., Schafe, G. E., & Burghardt, N. S. (2019). A diet enriched with curcumin promotes resilience to chronic social defeat stress. Neuropsychopharmacology, 44(4), 733–742. https://doi.org/10.1038/s41386-018-0295-2

Barnes P. J. (1998). Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clinical science, 94(6), 557–572. https://doi.org/10.1042/cs0940557

Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2018). Inflammatory responses and inflammation-associated diseases in organs. Oncotarget, 9(6), 7204-7218. https://doi.org/10.18632/oncotarget.23208

Cooper, J., Pastorello, Y., & Slevin, M. (2023). A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1087571

Dehzad, M. J., Ghalandari, H., Nouri, M., & Askarpour, M. (2023). Antioxidant and anti-inflammatory effects of curcumin/turmeric supplementation in adults: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Cytokine, 164, 156144. https://doi.org/10.1016/j.cyto.2023.156144

Dei Cas, M., & Ghidoni, R. (2019). Dietary curcumin: Correlation between bioavailability and health potential. Nutrients, 11(9), 2147. https://doi.org/10.3390/nu11092147

Dionisie, V., Filip, G. A., Manea, M. C., Manea, M., & Riga, S. (2021). The anti-inflammatory role of SSRI and SNRI in the treatment of depression: A review of human and rodent research studies. Inflammopharmacology, 29(1), 75–90. https://doi.org/10.1007/s10787-020-00777-5

Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C., Ferrucci, L., Gilroy, D. W., Fasano, A., Miller, G. W., Miller, A. H., Mantovani, A., Weyand, C. M., Barzilai, N., Goronzy, J. J., Rando, T. A., Effros, R. B., Lucia, A., Kleinstreuer, N., & Slavich, G. M. (2019). Chronic inflammation in the etiology of disease across the life span. Nature medicine, 25(12), 1822. https://doi.org/10.1038/s41591-019-0675-0

Hori, H. & Kim, Y. (2019). Inflammation and post-traumatic stress disorder. Psychiatry Clinical Neurosciences, 73, 143–153. https://doi.org/10.1111/pcn.12820

Huang, L., Chen, Z., Ni, L., Chen, L., Zhou, C., Gao, C., Wu, X., Hua, L., Huang, X., Cui, X., Tian, Y., Zhang, Z., & Zhan, Q. (2021). Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the inflammatory response and viral clearance in COVID-19 patients. Frontiers in Cardiovascular Medicine, 8. https://doi.org/10.3389/fcvm.2021.710946

Kim, T. D., Lee, S., & Yoon, S. (2020). Inflammation in post-traumatic stress disorder (PTSD): A Review of potential correlates of PTSD with a neurological perspective. Antioxidants, 9(2), 107. https://doi.org/10.3390/antiox9020107

Kopustinskiene, D. M., Masteikova, R., Lazauskas, R., & Bernatoniene, J. (2022). Cannabis sativa L. bioactive compounds and their protective role in oxidative stress and inflammation. Antioxidants, 11(4), 660. https://doi.org/10.3390/antiox11040660

Lee, B., & Lee, H. (2018). Systemic administration of curcumin affect anxiety-related behaviors in a rat model of posttraumatic stress disorder via activation of serotonergic systems. Evidence-based Complementary and Alternative Medicine. https://doi.org/10.1155/2018/9041309

Lopresti, A.L. (2022). Potential role of curcumin for the treatment of major depressive disorder. CNS Drugs 36, 123–141. https://doi.org/10.1007/s40263-022-00901-9

Mavaddatiyan, L., Khezri, S., & Abtahi Froushani, S. M. (2022). Effect of curcumin on cortisol, catalase and nerve growth factor expression level in animal model of induced multiple sclerosis. Journal of Gurgaon University Medical Sciences, 24(2). https://doaj.org/article/684c998f1a9f46dd8a3d3648212d1cb9

Medzhitov, R. (2021). The spectrum of inflammatory responses. Science. https://doi.org/abi5200

Memarzia, A., Khazdair, M. R., Behrouz, S., Gholamnezhad, Z., Jafarnezhad, M., Saadat, S., & Boskabady, M. H. (2021). Experimental and clinical reports on anti-inflammatory, antioxidant, and immunomodulatory effects of Curcuma longa and curcumin, an updated and comprehensive review. BioFactors, 47(3), 311–350. https://doi.org/10.1002/biof.1716

Monsey, M. S., Gerhard, D. M., Boyle, L. M., Briones, M. A., Seligsohn, M., & Schafe, G. E. (2015). A diet enriched with curcumin impairs newly acquired and reactivated fear memories. Neuropsychopharmacology, 40(5), 1278–1288. https://doi.org/10.1038/npp.2014.315

Nakahara, J., Masubuchi, Y., Takashima, K., Takahashi, Y., Ichikawa, R., Nakao, T., Koyanagi, M., Maronpot, R. R., Yoshida, T., Hayashi, S. M., & Shibutani, M. (2021). Continuous exposure to amorphous formula of curcumin from the developmental stage facilitates anti-anxiety-like behavior and fear-extinction learning in rats. Nutrition Research, 85, 99–118. https://doi.org/10.1016/j.nutres.2020.10.007

Nguyen, P., & Brewster, A. L. (2023). Who Dunnit? Angiotensin, inflammation, or complement: Unresolved. Epilepsy Currents. https://doi.org/10.1177/15357597221150057

Peng, Y., Ao, M., Dong, B., Jiang, Y., Yu, L., Chen, Z., Hu, C., & Xu, R. (2021). Anti-inflammatory effects of curcumin in the inflammatory diseases: Status, limitations and countermeasures. Drug Design, Development and Therapy, 15, 4503–4525. https://doi.org/10.2147/DDDT.S327378

Quinones, M.M., Gallegos, A.M., Lin, F.V., & Heffner, K (2020). Dysregulation of inflammation, neurobiology, and cognitive function in PTSD: An integrative review. Cognitive, Affective & Behavioral Neuroscience 20, 455–480. https://doi.org/10.3758/s13415-020-00782-9

Singletary, K. (2020). Turmeric: Potential health benefits. Nutrition Today 55(1), 45–56. DOI: 10.1097/NT.0000000000000392

Smith, D. N., Pungwe, P., Comer, L. L., Ajayi, T. A., & Suarez, M. G. (2023). Turmeric-associated liver injury: A rare case of drug-induced liver injury. Cureus, 15(3).

Sun, Y., Qu, Y., & Zhu, J. (2020). The relationship between inflammation and post-traumatic distress disorder. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.707543

Turmeric. (2022, March 21). In Drugs and Lactation Database (LactMed®). National Institute of Child Health and Human Development. Retrieved on April 38, 2023, from https://www.ncbi.nlm.nih.gov/books/NBK501846/

United States Department of Veteran Affairs (n.d.). PTSD: National Center for PTSD. Retrieved on April 23, 2023, from https://www.ptsd.va.gov/professional/treat/specific/trauma_discrimination_lgbtq.asp

Yadav, R., Jee, B., & Awasthi, S. K. (2015). Curcumin suppresses the production of pro-inflammatory cytokine interleukin-18 in lipopolysaccharide stimulated murine macrophage-like cells. Indian Journal of Clinical Biochemistry, 30(1), 109–112. https://doi.org/10.1007/s12291-014-0452-2

Zhou, X., Münch, G., Wohlmuth, H., Afzal, S., Kao, M., Low, M., Leach, D., & Li, C. G. (2022). Synergistic inhibition of pro-inflammatory pathways by ginger and turmeric extracts in rAW 264.7 cells. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.818166

Testimonials

“As a member of the AAPI community, I’m very familiar with the barriers to mental health services and the need to break through the glass wall of cultural stigma that prevents many from receiving potentially life–saving treatment. I was the only Asian American person in my master’s cohort, the only Asian American person in many of my clinical work settings, the only Asian American person to walk into many of the professional settings that I pushed myself to show up to. In my current practice, I’m constantly reminded by my patients of how difficult it is to find an Asian American mental health provider, though this reminder constantly informs me that more needs to be done for my community. Day after day, I read stories of Asian American people who die by suicide as a consequence of our culture’s avoidance of mental health topics. As a DBH, my biggest goal is to use my expertise in whole–person care to amplify the conversation around mental health and help my community understand that mental healthcare is not a privilege that we are not entitled to, it is a crucial part of our healthcare that will manifest differently in us than what many Western psychology or psychiatry textbooks will describe, and that our unique experience of mental health issues are valid, important, and is time to be part of the larger conversation.”
Willam Chum, LMHCDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - September 16, 2022

“The DBH represents something that I've always embraced in my professional career. And that's collaboration and working across a lot of different disciplines to make sure you’re delivering the best care for the patient. Everything is about being patient centered about finding innovative ways and creative ways to collaborate with other professionals.”
CDR Sean K. Bennett, LCSW, MSWAC, BCDDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - October 10, 2023

“This program will change how you present to the world, not just as a professional but as an individual. Understand this is work but the work is worth it and the journey is undeniably transformative. If you are seeking a doctorate for the title, this is not the program for you. If you are seeking a doctorate to interrupt and disrupt the course of healthcare, then this is the program for you. You won’t find a more supportive program with professors who are dedicated to your success and your education. This program is not about the regurgitation of information. It is about the appropriate applied application of knowledge and information to push forward and become an advocate for equitable and quality care for all.”
Brandy K. Biglow LMHC, CCTP, QSDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - February 5, 2024

“The Doctor of Behavioral Health (DBH) program has definitely transformed my understanding of behavioral health. Understanding the links between physical and mental health has taught how to make better treatment decisions. The DBH program has also given me insights that otherwise would not be possible and allows me to view individuals through a lens that I was previously ignorant of. This program has helped me grow into a more confident individual, provider, and parent.”
Cory H. Cannady, BCBA, LBADBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - March 13, 2024

“The DBH program has been a pivotal turning point in my understanding and application of behavioral health principles. Recently, the concept of ‘whole person health’ has gained widespread attention in healthcare circles, becoming somewhat of a buzzword. Like many others, I embraced this term, believing in my capacity to deliver comprehensive care.

Prior to my engagement with the program, my approach, albeit well-intentioned, lacked an appreciation for the intricate interplay between physical and mental health. More importantly, the role of unmet social needs as a catalyst for health disparities was a dimension I had not fully integrated into my practice. The DBH program illuminated these connections, offering me a robust framework to understand and address the multifaceted needs of individuals, especially within marginalized communities.

Additionally, the confidence I have gained through the DBH program extends beyond theoretical knowledge. My role as a connector and advocate for these individuals has become more pronounced, driven by a deep-seated commitment to fostering accessibility, equity, and comprehensiveness in care.”
Michelle Stroebel MA, NCC, LCMHC, NADD-CCDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - June 12, 2024

“I have worked in behavioral health for the entirety of my professional career starting with college internships up to my current role as Deputy Executive Commissioner of Behavioral Health for the Texas Health and Human Services Commission. While I have years of experience in the field, the DBH program at Cummings has framed my perspective as leveraging therapy as a first line of intervention. As a public servant, much of the work I do is usually in the aftermath of crises or when the system is being forced to respond to a service gap. However, the DBH program takes a much more proactive and integrative approach to health. This perspective/approach has the potential to positively shape policy in Texas in my role as a public servant charged with addressing the safety net needs of the most vulnerable constituents in Texas.”
Trina K. Ita, MA, LPCDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - July 10, 2024

“CGI feels like a community of long-lost cousins that finally met as adults and we realized that we share the same goals. The support from the faculty and classmates have been nothing short of amazing. I can reach out to my advisor at any given time to discuss course work, career endeavors, or to just vent about life. There is a feeling of closeness and belongingness at CGI that is just unmatched. I am very happy to be a member of the family and will continue to spread the word of how great this DBH program is.”
Michelle Francis, LCSW/LICSW-QSDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - September 10, 2024

“The DBH program’s mission, purpose, and objective say it all: We strive for intentional care outcome improvement practices that exemplify whole person-centered integrated healthcare advanced competency. The program of study drives insights and awareness of the ever-changing patient population and multidisciplinary practice environments to change how the world experiences healthcare. This is further reinforced by the pillars of medical literacy, integrated behavioral health intervention, and entrepreneurship skills and expertise. Development growth is needed to prepare the aspiring DBH for the future of the shifting healthcare marketplace through international networking in a growing community of disruptive innovators and an evolving movement toward systemic healthcare change. I feel that I will be positioned alongside a fellowship of like-minded professionals trying to improve the quality of healthcare service delivery value and outcome sustainability.”
Jose Mathew, LCSW, LAC, ACS, EMDR-T, CCTP-IIDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - October 8, 2024

“The DBH program has reinforced my vision of viewing behavioral health (BH) as an integrated component of the healthcare system rather than a siloed service. As a practitioner in the focused BH realm of substance use disorder (SUD) treatment, I observe on a regular basis how identifying and serving SUD patients is often missed, ignored and stigmatized in primary healthcare, despite the fact that early intervention at these check-points often has the potential to intervene earlier and lessen the negative SUD outcomes frequently seen by the time a patient reaches specialty SUD services. Reinforcement received in my DBH program has motivated me to promote integration as a leader in my workplace and is a primary factor in considering the long-term trajectory of my individual career path.”
Kenneth L. Roberts, MPS, LPCC, LADCDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - November 5, 2024

“By becoming a DBH, I have found that I am able to have different conversations with different people. Before having my doctorate degree, I was able to speak to certain items in behavioral health, but was only seen as a licensed therapist where as a doctor, I am able to speak to the changemakers and policy makers in a more collaborative manner which then allows us as a group to enhance the services we are providing. I also found that as a DBH, my confidence in the treatment room has improved immensely and cases that may have been more difficult for me before are no longer as difficult due to the training I have received in the program.”
Dr. Allison Earl, DBH, LPC-SDBH Alumna, Cummings Graduate Institute for Behavioral Health Studies - November 13, 2024

“I think the DBH is quite groundbreaking, it allows you to study from anywhere in the world. The support is fantastic, and you can make out of the DBH what you want. Unlike standard professional doctorates, the DBH was trying to break new ground, not trying to go over just old ground. It greatly encourages its students to be those people who break new ground.

As a person who actually has a disability, I found CGI staff to be very supportive, very accommodating. If I need extensions, they are always there. In fact the staff will reach out and check on you, if they haven’t heard from you in a very short period of time. Which I have never had from any other university.

I find the community of fellow DBH students absolutely wonderful, we reach out across numerous social media platforms, we email each other. Doesn’t matter where I am in the world or where they are in the world, everyone is supportive. Its support, support and encouragement with the DBH.”
Jason P. Sargent, B Policing, GDip Psych, MSW, JPDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - December 10, 2024

“Graduating from the DBH program has influenced and enhanced my approach to addressing behavioral health challenges and making a difference in the field by preparing me to become a serious business owner. Through the DBH program, I understand now that becoming a business owner not only assists me in reaping the financial benefits of working for myself, but the program also offers me a sense of freedom to make a difference in an individual’s life.”
Dr. Rebecca K. Wright, DBH, LBA, BCBA, QBADBH Alumna, Cummings Graduate Institute for Behavioral Health Studies - December 18, 2024

“I have always wanted to pursue a higher degree but never found a program that met my needs. When I investigated the DBH program, I can honestly say I was excited. It was a program that would expand my knowledge in behavioral health but also how it relates to physical health. The philosophy of treating the whole person was exactly what I was looking for.”
Elizabeth Nekoloff, M.Ed., LPCC-S, NCCDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - January 16, 2025

“Prior to obtaining my DBH, I practiced behavioral health within the boundaries of behavior analysis. The DBH degree has given me the ability to broaden my scope of competence allowing me to provide a higher quality of care to my clients through a person-centered approach, while still staying within my scope of practice. I was in the beginning stages of opening my business when I enrolled in the DBH program which set my trajectory towards being a stronger leader. The program equipped me with essential healthcare leadership and entrepreneurial skills, allowing me to ensure high-quality services for my clients and foster a supportive work environment for our staff. It has also given me the confidence to expand my business and pursue other healthcare ventures, reaching a broader range of patients in need.”
Dr. Pauline Tolentino Pablo, DBH, BCBA, IBADBH Alumna, Cummings Graduate Institute for Behavioral Health Studies - January 21, 2025

“Although I have worked with many patients who have mental health diagnoses, or behaviors which make managing their medical diagnoses and day to day life difficult, the DBH program at CGI is broadening that knowledge and providing a deeper understanding of behavioral health and how best to help these individuals manage their health and improve their quality of life. This will allow me to provide and advocate for more meaningful and seamless integrated care, providing new tools for my intervention toolbox, and the confidence and skills to collaborate within and lead whole person focused interdisciplinary teams. I also anticipate building upon my knowledge as a nurse case manager and long time caregiver, as well as my personal passions and professional vision, learning about processes and operations, to be in position to start up and lead my own company one day, offering the services and care I know every person should have access to.”
Hollie Wilson, MSN, RN, CCMDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - February 11, 2025

“The Doctor in Behavioral Health (DBH) program has changed my understanding of the subject and career path. Before this academic journey, my knowledge of behavioral health was primarily theoretical, including essential ideas and methods. However, the DBH curriculum combined intense academic research with practical application, helping me understand behavioral health from multiple angles. Recognizing mental health as part of total health changed my perspective. The biopsychosocial model, which showed how biological, psychological, and social variables affect mental health, was stressed in the DBH curriculum. This comprehensive approach made me realize how complex human behavior is and how important it is to address mental health issues. Effective interventions must target the individual’s surroundings, relationships, and life experiences, not just symptoms. The curriculum also gave me enhanced evidence-based practice training to execute successful solutions. Studies methods and data analysis classes improved my critical thinking and allowed me to evaluate and apply behavioral health studies. This gave me the confidence to contribute to the field’s knowledge base through practice and research.”
Dr. Rhea Hill, DBH, LPCDBH Alumna, Cummings Graduate Institute for Behavioral Health Studies - February 17, 2025

“The DBH program will open opportunities for me to contribute to healthcare system innovation, particularly through trauma-informed care and integrated behavioral health settings. I will be better positioned to advocate for and implement holistic care models that improve health outcomes for underserved populations. Ultimately, this program will help me transition into higher-level roles, such as a director or consultant in behavioral health, where I can influence broader system changes and contribute to the future of healthcare delivery.”
DeKyn Rashad Peters, MPH-CHES,BSW/BA,APCDBH Candidate, Cummings Graduate Institute for Behavioral Health Studies - March 4, 2025

“The DBH program has been integral in preparing me for leadership roles by providing a solid foundation in both the theoretical and practical aspects of leadership within the behavioral health sector. Through coursework, case studies, and hands-on experiences, I have learned to lead with empathy, data-driven decision-making, and strategic planning. The program has also honed my skills in organizational development, communication, and policy advocacy, equipping me to effectively lead teams, drive impactful change, and foster environments that promote positive behavioral health outcomes. With this training, I am confident in my ability to lead initiatives that address systemic barriers and improve care delivery.”
Dr. Jerrika Henderson, DBH, CMHCDBH Alumna, Cummings Graduate Institute for Behavioral Health Studies - March 18, 2025